MILGa-01: A first in human study to evaluate the safety and tolerability of monoclonal antibody conjugate MILGa (MIL-38/Gallium67) in patients with advanced prostate, bladder and pancreatic cancer
Latest Information Update: 12 Feb 2021
At a glance
- Drugs MILGa (Primary)
- Indications Bladder cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Ureteral neoplasms; Urethral cancer
- Focus Adverse reactions; First in man
- Acronyms MILGa-01
- Sponsors Minomic International
- 16 Feb 2019 Results assessing outcomes of the miltuximab presented at the 2019 Genitourinary Cancers Symposium.
- 16 Feb 2019 Status changed from recruiting to completed as per results presented at the 2019 Genitourinary Cancers Symposium.
- 09 Apr 2018 Planned End Date changed from 27 Apr 2018 to 26 May 2018.